Lisaftoclax (Synonyms: APG-2575; Bcl-2/Bcl-xl inhibitor 1) |
| Catalog No.GC64467 |
Lisaftoclax(화합물 6)는 특허 WO2018027097A1에서 추출한 항종양 활성을 갖는 이중 Bcl-2 및 Bcl-xl 억제제입니다. Lisaftoclax는 Bcl-2 및 Bcl-xl에 대해 각각 2nM 및 5.9nM의 IC50 값을 나타냅니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2180923-05-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lisaftoclax (compound 6) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively[1].
Lisaftoclax (compound 6) exhibits IC50 values of 5.5 nM and 6.4 nM in Bcl-2 dependent RS4;11 cells and Bcl-xl dependent Molm13 cells[1].
[1]. WANG, Chia, et al. N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS. Patent. WO2018027097A1.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *